ESR1 and breast carcinoma: Although targeted therapies for estrogen receptor–positive (ER+) and ERBB2-amplified (human epidermal growth factor receptor 2–positive [HER2+]) breast cancers have become the mainstay of treatment over several decades, a rapidly growing number of novel agents are now emerging whose effectiveness may depend on specific genomic aberrations.